As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains

MUMBAI - Patent expiries on biotech-based drugs starting in 2012 accompanied with a clearer regulatory framework will throw open a $10 billion market opportunity for biosimilars in the U.S. and Europe; Indian companies including Dr. Reddy's, Intas, Wockhardt and Ranbaxy are all bolstering their product pipelines to prepare for those markets